Brentuximab vedotin in Hodgkin's lymphoma

Bibliography

• Horner MJ, Ries LAG, Krapcho M, SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Available from: http//seer.cancer.gov/csr/1975_2006/
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press; Lyon, France: 2008
   Google Scholar
• Schmitz N, Pfistner B, Sextro M, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002;359:2065-71
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, New prognostic score based on treatment outcome of patients with Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
   PubMed Web of Science ®Google Scholar
• Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 1997;27:195-205
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Younes A, Carabasi MH, A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-54
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Blum KA, Jung SH, Johnson JL, Serious pulmonary toxicity in patients with Hodgkin's lymphoma treated with the anti-CD30 antibody, SGN-30, and gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) is associated with a FcgammaRIIIa-158 V/F polymorphism; results from CALGB 505502. Ann Oncol 2010;21:2246-54
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large cell lymphoma. J Clin Oncol 2007;25:2764-9
   PubMed Web of Science ®Google Scholar
• Thertulien R, Frankel AE, Evens AM, A Phase I, open label, dose-escalation, multidose study of MDX-1401 (defucosylated human anti-CD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma [abstract 1227]. AACR Meeting Abstracts; 2009
   Google Scholar
• Blum KA, Smith M, Fung H, Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy [abstract 8531]. J Clin Oncol 2009;27:15s
   Google Scholar
• Bross PF, Beitz J, Gang C, Approval summary: gentuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-6
   Google Scholar
• Dubowchik GM, Firestone RA, Padilla L, Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 2002;13:855-69
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug-conjugate. Clin Cancer Research. 2010;16(3):888-97
   Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD-30 positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30 positive hematologic malignancies. Clin Cancer Res 2012;18:248-55
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AJ, Smith SE, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; Epub ahead of print
   Google Scholar
• Wagner-Johnston ND, Bartlett NL, Cashen A, Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012
   Google Scholar
• Younes A, Connors JM, Park SI, Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010;118:995
   Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALBG 59804. Ann Oncol 2007;18:2615-19
   Google Scholar
• Baetz T, Belch A, Couban S, Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-7
   PubMed Web of Science ®Google Scholar
• Gopal AK, Press OW, Shustov AR, Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the puget sound oncology consortium. Leuk lymphoma 2010;51:1523-9
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA, Gerecitano J, Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 2009;114:abstract 720
   Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem- cell transplantation: results of a phase II study. J Clin Oncol 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, A pilot study of rituximab in patients with recurrent classic Hodgkin disease. Cancer 2003;98:310-14
   PubMed Web of Science ®Google Scholar
• Bartlett N, Grove LE, Kennedy DA, Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series. J Clin Oncol 2010;28:8062
   Google Scholar